RedKnight in numbers

127

Proposals Submitted

52

Proposals Approved

41%

Success rate

£4.79m

of funding secured

6

Seal of excellence awards

7

Company awards

Since launching in September 2015, RedKnight has secured over £4.78 million of funding to support our clients’ innovative products, processes and services, of which over £2 million have been awarded to Welsh companies. Helping Wales based companies grow is RedKnight's core mission, but that does not mean we don't work further afield. Since day one, we have set a global reach that has allowed us to work with over 100companies around the world.

Here is a selection of some of our most recent successes. Please hover over projects to view more.

null

£68,583

Innovate UK

Metis

The project Metis, developed by Bond Digital Health Solutions, aims to create a wereable technology that can provide a digital solution to the current void that exists between patients suffering with Chronic Obstructive Pulmonary Disease (COPD) and their doctors. Such ``clinical whitespace`` often causes a dramatic loss of relevant patient data which could be better used to provide more effective COPD management.
Thanks to this grant, Bond will be able to further develop the product which will equip medical practitioners with independent, accurate analysis of patient data providing valuable, comprehensive insights and evidence-based care.

null

£819,988

Innovate UK

DeepADMET

The DeepADMET project aims to develop a Next-Generation Platform for Novel Drug Discovery, using Deep Learning of ``absorbption, distribution, metabolism and excretion-toxicity`` (ADMET properties). Poor ADMET properties are the cause of almost 56% of drug failures in pre-clinical and clinical development, generating upd to $1.4bn losses worldiwide. Thanks to DeepADMET, a new modelling method is now available: by employing modern ‘Artificial Intelligence’ (AI) methods and applying these methods to modelling pre-gathered ADMET data, researchers can now provide more robust and precise ADMET properties.

null

€632,812

Eureka Eurostars

MISCA

Funded through the Eureka Eurostars Actions within the H2020 Programme, MISCA aims to provide Monolitically Integrated detector Solutions for next-generation Comms Applications. Current optical communications infrastructures cannot sustain the increasing bandwith demand, without massively increase power consumption. Thus, MISCA uses intelligent monolithic integration of compound semiconductor materials platforms to deliver high-speed detector solutions with co-optimised RF and optical performance, to deliver increased chip-scale specification and reduce operating power requirements.

null

€50,000

SME Instrument

Podium

Funded by the SME Instrument within the H2020 programme, Thermetrix’s disruptive technology PODIUM uses a combination of thermochromic liquid crystal sheet and high-res cameras, to provide a state-of-the-art diabetic foot monitor that can provide accurate early warning on the formation of Diabetic Foot Ulcers (DFUs). The thermal patterns so picked up by PODIUM will be transmitted to a cloud portal helping patients, family and medical staff to detect and immediately treat conditions before the onset of ulceration. In this way, stress and inflammation can be reduced, tissue damage limited and the foot will return to normal. Critically, up to 80% of DFUs may be avoided.

null

€2.3M

Fast Track to Innovation

BreathSpec®

The BreathSpec project aims to develop a rapid, non-invasive device that can diagnose bacterial or viral infections through ultra-high sensitivity breath analysis.
Once developed the BreathSpec device will help reduce the development of anti-bacterial resistance and alleviate the growing problem of antimicrobial resistance (AMR) through improved diagnosis of antibiotic treatment. The device will also reduce the scientific, clinical and financial challenges associated with the development of new antibiotics.

null

£96,952

Innovate UK

CADDNOR

The CADDNOR project aims to develop a point of care (POC) diagnostics and carbohydrate-based therapeutics, focused on the detection of Norovirus. The developed assay uses glyconanoparticle technology with potential for replacing molecular technologies and immunodiagnostics – a major shift in analytical approach. The use of carbohydrates instead of antibodies as the recognition mechanism has several advantages including their production using industrial scale, cost-effective chemoenzymatic synthesis which addressed the call topic.

null

€274,500

Horizon 2020

TALK

Funded through the Marie Sklodowska-Curie Actions, TALK aims to guide multi-professional clinical teams learning and improve the quality of patient care and safety. Consisting of 5 partners across 3 countries, TALK will research the benefits of structured debriefing, communication and organisational culture. Using this data, further training materials will be developed and translated to support the wider deployment of the tool, which will be widely disseminated and implemented across and beyond all participating partners.

null

£130,636

Innovate UK

STELA

TeloNostiX’s disruptive technology can predict the outcome of common cancer types, e.g. CLL, and identify patients who do and do not require early treatment; a precision hitherto impossible to achieve.
This project aims to achieve two objectives (i) Demonstrate the technical feasibility of telomere testing in the routine clinical management of CLL patients (ii) Create a financial justification for NHS adoption by undertaking health economics modelling.